Roche - Doing now what patients need next

HPV DNA Test with HPV-16 and -18 genotyping

Creating Value for Patients

Persistent infection with high-risk human papillomavirus (HPV) is the leading cause of cervical cancer, implicated in more than 99 percent of all cases.

The World Health Organization estimates there are 470,000 new cases of cervical cancer annually.

Navigate the thumbnails to learn more.

Learn more about HPV screening

Screening enables early identification and removal of pre-cancerous lesions, dramatically reducing the incidence and mortality of cervical cancer worldwide.

The most commonly used test to detect cervical cancer is the "Pap smear" – but many women ultimately diagnosed with cervical cancer had normal Pap smear results.

High-risk HPV testing

Of the more than 118 different types of HPV, 13-16 types
are currently considered high-risk for the development of cervical cancer and its precursor lesions.

HPV types 16 and 18 have been identified as the highest risk genotypes, detected in approximately 70 percent of cervical cancers.

Proving medical value of a diagnostic test through a clinical trial

The Roche ATHENA trial enrolled over 47,000 women, screening participants for cervical cell changes using both the Pap smear and the HPV DNA Test for 14 high-risk HPV genotypes.

> More information on the ATHENA Trial
> More information on the HPV DNA Test

Did you find this feature informative?

Yes

Please feel free to leave additional comments: